Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1118626
Reference Type
Journal Article
Title
Operation design for controlling polymorphism in the anti-solvent crystallization by using ternary phase diagram
Author(s)
Takiyama, H; Minamisono, T; Osada, Y; Matsuoka, M
Year
2010
Is Peer Reviewed?
Yes
Journal
Chemical Engineering Research and Design
ISSN:
0263-8762
EISSN:
1744-3563
Volume
88
Issue
9A
Page Numbers
1242-1247
DOI
10.1016/j.cherd.2009.09.011
Web of Science Id
WOS:000282246600018
Abstract
In the pharmaceutical production, to control polymorph formation is important from the viewpoint of the productivity and the bioavailability. Anti-solvent or drowning-out crystallization is widely used in the pharmaceutical industry for high yield production. However, anti-solvent addition method to control polymorph formation in anti-solvent crystallization has not been discussed enough. In this study, indomethacin (IMC) which has three polymorphs was used. The purpose of this study is to establish a production method of the target polymorph in the anti-solvent crystallization (IMC-acetone-heptane system). The simulation model for determination of anti-solvent feed rate based on the ternary phase diagram was proposed. The stability of the polymorph of IMC crystal in the solution was changed not only with temperature but also with composition of the mixed solvent. From the experimental and simulation results, the design strategy of anti-solvent crystallization was proposed. (C) 2009 The Institution of Chemical Engineers. Published by Elsevier B.V. All rights reserved.
Keywords
Anti-solvent; Polymorphism; Ternary phase diagram
Tags
•
Methanol (Non-Cancer)
Search 2012
WOS
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity